Dissolution of large intracardiac thrombus, potential role of the emerging oral fibrinolytic agent
Abstract: Intracardiac
thrombus may persist in some cases even after anticoagulant therapy. This opens
a possibility to add a potent thrombolytic agent into therapeutic regimen
without increasing bleeding risk any further. Increasing evidence showed a
promising efficacy and safety of oral fibrin specific lumbrokinase as a
thrombolytic agent. To the best of our knowledge, report of the use of
lumbrokinase on intracardiac thrombus is limited. We reported two cases of
intracardiac thrombi. In first patient, after two-month therapy with
lumbrokinase, the previous 8 cm2 left atrial thrombus was completely
disappeared. Second patient had left ventricular thrombus due to low left
ventricular ejection fraction caused by coronary artery disease. A significant
dissolution in thrombus size on repeated follow-up was found. Both patients did
not experience any significant adverse effect. This case series aims to present
the potential use of lumbrokinase as as oral antithrombotic therapy in
intracardiac thrombus.
Author: Rony M. Candrasatria,
Manoefris Kasim
Journal Code: jpkedokterangg160143